Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Journey Medical (DERM) EBIT Margin (2020 - 2025)

Journey Medical's EBIT Margin history spans 6 years, with the latest figure at 34.55% for Q4 2025.

  • For the quarter ending Q4 2025, EBIT Margin rose 1685.0% year-over-year to 34.55%, compared with a TTM value of 3.94% through Dec 2025, up 2087.0%, and an annual FY2025 reading of 3.9%, up 2091.0% over the prior year.
  • EBIT Margin for Q4 2025 was 34.55% at Journey Medical, up from 8.98% in the prior quarter.
  • The five-year high for EBIT Margin was 112.87% in Q3 2023, with the low at 90.02% in Q2 2021.
  • Average EBIT Margin over 5 years is 26.03%, with a median of 22.54% recorded in 2024.
  • Year-over-year, EBIT Margin skyrocketed 17177bps in 2023 and then plummeted -13265bps in 2024.
  • Tracing DERM's EBIT Margin over 5 years: stood at 51.7% in 2021, then crashed by -45bps to 75.2% in 2022, then skyrocketed by 82bps to 13.79% in 2023, then soared by 228bps to 17.7% in 2024, then skyrocketed by 95bps to 34.55% in 2025.
  • Per Business Quant, the three most recent readings for DERM's EBIT Margin are 34.55% (Q4 2025), 8.98% (Q3 2025), and 19.16% (Q2 2025).